Disease Landscape and Forecast Insights

Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body, and its symptoms range from general malaise to serious, CNS and renal manifestations…

Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for…

Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (…

AS is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness…

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and…

Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (sUA). Treatment of the painful acute flares is distinct from the chronic management of…

Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Asthma pharmacotherapy has two main goals: address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals—maintenance therapy (e.g…

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices, taking into account attributes such as…